| scholarly article | Q13442814 |
| P2093 | author name string | A K Singh | |
| W Shapiro | |||
| D W Coyne | |||
| A R Rizkala | |||
| DRIVE Study Group | |||
| P2860 | cites work | Acute-phase proteins and other systemic responses to inflammation | Q28296941 |
| Iron indices: what do they really mean? | Q36531876 | ||
| Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. | Q40876012 | ||
| The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin | Q43654523 | ||
| Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease | Q43882886 | ||
| Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients | Q46217820 | ||
| Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. | Q52205936 | ||
| Effective utilization of erythropoietin with intravenous iron therapy. | Q52866695 | ||
| Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. | Q53938176 | ||
| Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study | Q61371441 | ||
| Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients | Q73484885 | ||
| IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 | Q73566942 | ||
| Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure | Q73782135 | ||
| Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients | Q73894320 | ||
| Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients | Q73989446 | ||
| A randomized trial of iron deficiency testing strategies in hemodialysis patients | Q77333789 | ||
| Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients | Q78498324 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| hemodialysis patient | Q126109077 | ||
| P304 | page(s) | 1163-1171 | |
| P577 | publication date | 2007-03-28 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation | |
| P478 | volume | 71 |
| Q46141374 | Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study |
| Q90239041 | Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study |
| Q37347851 | Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial |
| Q34989324 | Correction of iron deficiency in the cardiorenal syndrome |
| Q39192941 | Diagnosing and preventing iron overload |
| Q38566828 | Diagnosis of iron-deficient states |
| Q36677375 | Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin |
| Q46228247 | Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation |
| Q37211057 | Hepcidin--a potential novel biomarker for iron status in chronic kidney disease |
| Q28727076 | Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents |
| Q33625004 | Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients |
| Q35003742 | Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients |
| Q37890241 | Hepcidin: clinical utility as a diagnostic tool and therapeutic target |
| Q38114158 | How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis |
| Q58700150 | Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease |
| Q39582910 | Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. |
| Q38087947 | Intravenous Iron Repletion Does Not Significantly Decrease Platelet Counts in CKD Patients with Iron Deficiency Anemia |
| Q37807903 | Intravenous iron in heart failure: beyond targeting anemia |
| Q35022235 | Iron dosing in kidney disease: inconsistency of evidence and clinical practice |
| Q37801274 | Iron supplementation to treat anemia in patients with chronic kidney disease |
| Q33770044 | Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response |
| Q64064176 | Molecular perspective of iron uptake, related diseases, and treatments |
| Q30313877 | Plasma vitamin C levels in ESRD patients and occurrence of hypochromic erythrocytes. |
| Q47835950 | Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. |
| Q35115561 | Renal anemia: a nephrologist's view. |
| Q36666984 | Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients |
| Q44712530 | Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival |
| Q36133152 | The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients |
| Q37542851 | The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients |
| Q45264148 | Variability of ferritin measurements in chronic kidney disease; implications for iron management. |
Search more.